Effettuare il login Iscriviti gratis

Cellectis Entrate Y/Y

Cos'è Entrate Y/Y di Cellectis?

Entrate Y/Y di Cellectis è -53.05%

Qual è la definizione di Entrate Y/Y?

La crescita annuale dei ricavi degli ultimi 3 anni è la crescita dei ricavi da un anno all'altro in media negli ultimi 3 anni.

The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.

Entrate Y/Y di aziende nel Health Care settore su NASDAQ rispetto a Cellectis

Cosa fa Cellectis?

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

Aziende con entrate y/y simili a Cellectis